(c) whether it is a fact that import contents in the production from intermediate stage is more than the CIF price of the imported drug;

(d) what are the imported intermediates used by the companies and what is the import content per kg. of production of Vitamin B6;

(e) whether it is a fact that Vitamin B6 is price decontrolled; and

(f) if so, what steps have been taken to rectify the situation?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) Two companies namely M|s. IDPL and M|s. Lupin Lab Ltd., are producing Vit. B6 bulk drug from DL-Alanine and Ethyl Aceto Acetate Stage respectively.

(c) and (d) The CIF price of Vit. B6 ranges from US $ 35.00 to 40.00 (around Rs. 540 to Rs. 620 per kg.) whereas as per the information received from the Companies, the CIF price for imported raw materials going into the production of I kg. of Vit. B6 is approximately Rs. 212 for M|s. IDPL and Rs. 204.34 for M|s. Lupin Labs Ltd.

Both the companies are using four imported raw materials as per details given below:-

M/s. IDPL

1. DL-Alanine
2. Disbutenediol
3. Dimethyl Formamide.
4. Isobutyraldehyde

M/s. Lupin Lab Limited

1. Ethyl Aceto Acetate
2. Formamide.
3. Butenediol
4. Isobutyraldehyde.

(e) Yes, Sir.

(f) Does not arise, in view of information at (c) and (d) above.

Concentration aspect in the Kelkar Committee Report

1454. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the Kelkar Committee has not defined concentration in the Report;

(b) what is the meaning of concentration as adopted by the Committee;

(c) whether his Ministry has examined the criteria of concentration and its meaning;

(d) whether it is also a fact that concentration aspect has been ignored in several instances;

(e) whether his Ministry has come across such instances; and

(f) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (f) The relevant papers are being looked into and information, to the extent available, will be laid on the Table of the House, as early as possible.

Shifting of Rifampicin from Category-I to Category-II

1455. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Kelkar Committee observed cartel formulation in the import of intermediate as well as bulk drug while recommending shifting of Rifampicin from Category-I to Category-II;

(b) whether it is a fact that committee discussed to allow free imports of both to prevent cartel formulation;

(c) whether Committee made any recommendations in respect to free imports and overinvoicing; and